参一胶囊联合替吉奥胶囊治疗老年晚期非小细胞肺癌临床观察  

Clinical Observation of Shenyi Capsule Combined with Tiji'ao Capsule in the Treatment of Elderly Advanced Non-Small-Cell Lung Carcinoma

作　　者：宋春燕[1] 王翠英[1] 

机构地区：[1]衡水市第四人民医院,河北衡水053000

出　　处：《中医学报》2015年第4期470-471,共2页Acta Chinese Medicine

摘　　要：目的：观察参一胶囊联合替吉奥胶囊治疗老年晚期非小细胞肺癌的临床疗效。方法：选取32例老年晚期非小细胞肺癌患者作为研究对象，将替吉奥胶囊按体表面积分3个等级给药，每日2次，早晚餐后口服，连续给药28d，休息14d，为1个治疗周期。口服替吉奥胶囊的同时服用参一胶囊，每日2次，每次2粒，治疗2周期后评价疗效。结果：32例患者中，完全缓解2例（6．25％），部分缓解12例（37．50％），稳定9例（28．13％），进展9例（28．13％），有效率43．75％，疾病控制率71．88％。不良反应为骨髓抑制及消化道反应，骨髓抑制发生率为21．90％，主要为Ⅰ ～Ⅱ度骨髓抑制，消化道不良反应轻，发生率18．60％．主要为Ⅰ ～Ⅱ度不良反应。结论：参一胶囊联合替吉奥胶囊治疗老年晚期非小细胞肺癌具有增效减毒的功效。Objective：To observe the clinical curative effect of Shenyi capsule combined with Tiji＇ao capsule in the treatment of elderly advanced non-small-cell lung carcinoma. Methods：Choose 32 cases of elderly patients with advanced non-small cell lung cancer as the research object. Tiji＇ao capsule was divided into three levels according to surface integral ,2 times a day, dinner early oral, continuous for 28d,rest for 14d,as a treatment cycle. At the same time were given Shenyi capsule, two times a day, every time 2 grains. Evaluate the curative effect of 2 cycles. Results： 32 cases of patients, complete remission in 2 cases （6.25%）, partial remission in 12 cases （37. 50% ） ,stable in 9 cases（28.13% ） ,progress in 9 eases（28.13% ） ,effective rate was 43.75% and the control rate was 71.88%. The adverse reactions in bone malTOW suppression and gastrointestinal reaction and bone marrow inhibition rate was 21.90% , mainly for Ⅰ ～Ⅱdegrees. The incidence of gastrointestinal adverse was 18.60% mainly for Ⅰ ～Ⅱ degree. Conclusion：Shenyi capsule combined with Tiji＇ao capsule in the treatment of elderly advanced non-small-eell lung carcinoma has better effect.

关 键 词：老年晚期非小细胞肺癌 参一胶囊 替吉奥胶囊 

分 类 号：R273.42[医药卫生—中西医结合]